The Zacks Analyst Blog Highlights: Moderna, Pfizer, BioNTech, Sanofi and GlaxoSmithKline

Tuesday, 26 May 2020, 14:52:00
The Zacks Analyst Blog Highlights: Moderna, Pfizer, BioNTech, Sanofi and GlaxoSmithKline
— Zacks Investment Research

Research Report with COVID-19 Forecasts – Post-traumatic Stress Disorder Therapeutics Market 2020-2024 | Rising Prevalence of PTSD to Boost Growth | Technavio

Monday, 25 May 2020, 20:30:00
Technavio has been monitoring the post-traumatic stress disorder therapeutics market and it is poised to grow by USD 909.86 million during 2020-2024, progressing at a CAGR of over 9% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200525005262/en/ Technavio has announced its latest market research report titled Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Market 2020-2024 (Graphic: Business Wire) Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Please Request Free Sample Report on COVID-19 Impact The market is fragmented, and the degree of fragmentation will accelerate during the forecast period. AstraZeneca Plc, Azevan Pharmaceuticals Inc., Bionomics Ltd., Eli Lilly and Co., GlaxoSmithKline Plc, H.
— Benzinga Feeds

Major pharma companies rejected a 2017 EU proposal that could let vaccines for viruses like the coronavirus be developed before an outbreak

Monday, 25 May 2020, 10:21:00
A 2017 proposal that would speed up vaccine production in the EU was blocked by major pharmaceutical companies, The Guardian reported . The proposal would fund improvements to testing, potentially allowing approval to be fast-tracked and for vaccines against viruses like the novel coronavirus to be developed before an outbreak begins. But it was rejected by the pharmaceutical companies on the IMI, a body dedicated to improving the EU’s pharmaceutical research. Representatives of a group that includes GlaxoSmithKline, Novartis, Pfizer, and Johnson & Johnson are part of that body, The Guardian reported . The IMI rejected the claim that it has focused on other illnesses to the detriment of the coronavirus, pointing to investments it has made in vaccines and in light of the Ebola outbreak. Companies are now rushing to try and create an effective vaccine to tackle the pandemic. Visit Business Insider’s homepage for more stories . The world’s biggest pharmaceutical companies blocked a 2017 EU proposal that could allow vaccines against viruses like the novel coronavirus to be developed before an outbreak begins, The Guardian reported .
— Business Insider

£1K to invest? I’d buy AstraZeneca or GSK pharma shares for a rich retirement

Sunday, 24 May 2020, 13:45:59
Pharma bellwethers AstraZeneca (LON: AZN) and GlaxoSmithKline plc (LON: GSK) may be robust additions to a long-term portfolio, helping investors retire rich The post £1K to invest? I’d buy AstraZeneca or GSK pharma shares for a rich retirement appeared first on The Motley Fool UK .
— The Motley Fool UK

The untold story of Moderna as the biotech’s coronavirus vaccine faces a test that could make it one of the most consequential startups of all time (MRNA)

Saturday, 23 May 2020, 11:45:00
The biotech Moderna has skyrocketed to global prominence, leading the world’s race for a coronavirus vaccine. The Cambridge, Massachusetts-based biotech was founded in 2010 with the ambitious goal to develop a new type of medicine. While its platform remains unproven, it is now being tested under the brightest possible spotlight of a pandemic. Here’s the inside story of Moderna’s rise, from an offshoot of stem cell research to routinely shattering funding records on its way to biotech’s top ranks. The biotech has spent a decade working to meet this moment, and investors have sent its stock soaring to a valuation of almost $30 billion. The next few months will be a defining period for the future of Moderna. Visit Business Insider’s homepage for more stories . In its short corporate history, Moderna has grown accustomed to breaking records. A $450 million funding round in 2015 was a record for the biotech industry. Moderna raised even more the next year. And its 2018 initial public offering was the largest ever for a biotech .
— Business Insider